Role of FDG PET, Immune and Hypoxic Marker in NSCLC

N/ACompletedNCT02519062

Istituto Clinico Humanitas130 enrolled

Overview

This is a retrospective study that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of maximum 130 patients with NSCLC treated with surgery with radical intent at our center.

This is a retrospective observation that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of 130 patients with NSCLC treated with surgery with radical intent at our center. We will review FDG-PET acquired within 30 days prior to surgery and analyze its principal imaging characteristics with respect to hypoxic and immune-related markers at immunohistochemistry (IHC). These markers will be studied on tumor tissue obtained at surgery, used for diagnostic purposes and stored in paraffin.

Study Type

OBSERVATIONAL

Enrollment

130

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

No interventionOTHER

This is a retrospective study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of NSCLC (Stage I-III) * FDG PET before surgery Exclusion Criteria: * Absence of tumor specimen * No clinical data * FDG-PET can not be evaluated

Locations (1)

Istituto Clinico Humanitas

Rozzano, Milano, Italy

Outcomes

Primary Outcomes

Correlation of SUVmax (Maximal Standardized Uptake Value) in patients with non-small cell lung cancer undergoing surgery with hypoxia expression and tumor immune cell infiltration.

Time frame: Baseline SUVmax up to 1 month before surgery.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.